Androgen receptor CAG repeats, non-random X chromosome inactivation, and loss of heterozygosity at Xq25 in relation to breast cancer risk

Table 1 Frequency of heterozygosity and LOH in breast cancer and other cancer tissue

Sample	Breast Cancers (BC)				Other Cancers (OC)		P
marker	Heterozygosity/No. of BC	Heterozygosity %	LOH/informative^a	LOH^b %	LOH/informative	LOH %	value^c
DXS8067	29/65	44.6%	13/29	44.83%	5/17	29.4%	0.47
DXS1001	56/65	86.2%	17/56	30.36%	6/19	31.6%	0.85
DXS8059	34/65	52.3%	13/34	38.24%	1/8	12.5%	0.17
DXS8098	46/64	71.9%	13/46	28.24%	7/17	14.1%	0.50
DXS8009	50/64	78.1%	14/50	28.00%	6/16	37.5%	0.68
DXS1047	55/65	84.6%	26/55	47.23%	5/20	25.0%	0.14
DXS8068	49/65	78.5%	20/51	39.22%	5/16	31.2%	0.78
DXS8078	20/59	33.9%	4/20	20.00%	1/14	7.1%	0.379
DXS8071	13/58	22.4%	4/13	30.77%	0/14	0.0%	0.041
DXS8041	46/58	79.3%	9/46	19.57%	4/21	19.0%	0.676
DXS8074	32/58	55.2%	11/32	34.38%	2/15	13.5%	0.175
Xq25			46/65	70.7%	10/25	40.0%	0.014

The frequency of heterozygosity and LOH in the breast cancers (BC) and other cancers (OC) are presented in this table.
a. informative: patients with heterozygosity.
b. LOH %: number of patients with LOH divided by number of patients with heterozygosity.
c. Chi-square test and Fisher’s exact probability test.

ISSN: 1471-2407